
NVIDIA BioNeMo Platform Secures Lilly and Thermo Fisher as AI Drug Discovery Partners
NVIDIA has positioned its BioNeMo platform as core infrastructure for biotech AI, securing partnerships with pharmaceutical giants Eli Lilly and Thermo Fisher Scientific.<sup>1</sup> The platform enables biotech startups including Terray, Apheris, Natera, and Basecamp Research to build foundation models for drug discovery. This expansion mirrors NVIDIA's GPU dominance strategy in a vertical market with substantial R&D budgets.

